---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-028075"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:54:55.925375+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Akari raises ~$5M in equity; exchanges $4M notes for warrants

## Summary
- Gross proceeds ~$5M from 10,043,774 ADSs at $0.3883/unit plus pre-funded warrants to insiders for $1M+.
- Non-cash reduction of ~$4M in 2026 Notes via exchange for pre-funded warrants and Note Exchange Warrants.
- Warrants exercisable after shareholder approval; Series G exercise price $0.3883, 5-year term.
- Ladenburg Thalmann acts as placement agent; 8.0% fee, 0.5% mgmt fee, and 504,300 placement agent warrants.
- Net proceeds for R&D and working capital; offering closed Dec. 17, 2025.

## SEC filing metadata
- accession: 0001493152-25-028075
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 1.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000149315225028075/0001493152-25-028075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000149315225028075/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-028075
- JSON: https://secwatch.observer/filing/0001493152-25-028075.json
- Plain text: https://secwatch.observer/filing/0001493152-25-028075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.